🇺🇸 FDA
Pipeline program

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

TAK-079-1006

Phase 1 other active

Quick answer

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy for IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease) is a Phase 1 program (other) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
Phase
Phase 1
Modality
other
Status
active

Clinical trials